- ContraFect Corporation (NASDAQ:CFRX) shares are trading higher Thursday morning. However, there is no specific news to justify the move.
- Wednesday morning, ContraFect announced the dosing of the first patient in Phase 1b/2 of exebacase in the setting of an arthroscopic debridement, antibiotics, irrigation, and retention procedure in patients with chronic prosthetic joint infections of the knee due to Staphylococcus aureus or Coagulase-Negative Staphylococci.
- The study was initiated earlier this month.
- ContraFect stock is gaining on heavy volume, with a session volume of 55 million shares traded, compared to the trailing 100-day volume of 3.08 million shares.
- According to data from Benzinga Pro, CFRX has a 52-week high of $362.4 and a 52-week low of $0.90.
- Price Action: CFRX shares are up 68.20% at $2.22 on the last check Thursday.
Tesla Investor Sees Apple Selling More Vision Pros In 2024 Than EV Giant Delivering Cybertrucks: ‘This Bet Is Not Looking Good’
Ross Gerber, the president and CEO of Gerber Kawasaki Wealth and Investment Management and a Tesla Inc (NASDAQ:AAPL) selling more Vision Pro…
